Biovaxys Technology Corp (TSE:BIOV) has released an update.
BioVaxys Technology Corp., a biopharmaceutical company, is currently delaying its required annual and interim financial statements due to an extended audit process, with its management cease trade order (MCTO) now extended until May 13, 2024 by the Ontario Securities Commission. Despite these delays, the company reassures that no other material changes or defaults have occurred and is committed to fulfilling the alternative information guidelines. BioVaxys is known for its innovative immunotherapies and clinical stage pipeline addressing various medical conditions including cancers and infectious diseases.
For further insights into TSE:BIOV stock, check out TipRanks’ Stock Analysis page.
